Why the study?
To provide a concise overview of the 2021 ACC update on heart failure treatment, highlighting developments regarding ARNI, SGLT2 inhibitors, and percutaneous mitral regurgitation management.
This paper provides a concise summary of the 2021 ACC expert consensus decision pathway for heart failure management, highlighting the integration of ARNI and SGLT2 inhibitors into standard care.
ACC 2021 HF update elevates ARNI and SGLT2i roles; leaves open ESC confirmation and practice impact.
Na zaÄĂĄtku roku 2021 vydala American College of Cardiology (ACC) update k lĂŠÄbÄ srdeÄnĂho selhĂĄnĂ v Äa-sopise Journal of the American College of Cardiology. PĹinĂĄĹĄĂme struÄnĂŠ informace z tohoto dokumentu. OÄekĂĄvĂĄ se, Ĺže EvropskĂĄ kardiologickĂĄ spoleÄnost (ESC) vydĂĄ v tomto roce novĂĄ guidelines, kterĂĄ pravdÄpo-dobnÄ potvrdĂ tento update, pĹedevĹĄĂm co je novĂŠho v postavenĂ sacubitril/valsartanu (inhibitoru receptoru angiotenzinu a neprilysinu, ARNI) a inhibitorĹŻ sodĂkoglukĂłzovĂŠho kontransportĂŠru 2 (SGLT2) jako novĂŠ lĂŠkovĂŠ skupiny pro lĂŠÄbu srdeÄnĂho selhĂĄnĂ. NovĂ˝ je i perkutĂĄnnĂ pĹĂstup k lĂŠÄbÄ mitrĂĄlnĂ regurgitace. CelĂ˝ dokument mĂĄ 32 stran.
No takes yet. Share an insight, caveat, or question.
Špinar et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: